News & Podcast

Outpatient surgery is gaining momentum, yet isolated solutions, media discontinuities, and even fax machines often slow down operations. Founded in 2024, the startup Ambuflow is developing an end-to-end operating system specifically for outpatient surgery centers. In an interview, co-founder Johannes Hargasser, who also works as an anesthesiologist, explains how Ambuflow aims to simplify administration, boost revenues, and free up more time for patient care.

From Munich quantum research to personalized medicine: Qtas, a startup founded in 2025 by Robin Allert, Karl Briegel, and Nick von Grafenstein, develops technology that makes extremely rare tumor cells in blood samples visible and analyzable. In the interview, CEO Robin Allert explains how personal experiences and quantum sensing formed the foundation for the company.

Apply now: Solve for Tomorrow is looking for ideas in the areas of health, sustainability, and social inclusion. The application deadline for the funding program runs until June 23, 2026.

Fresenius is joining Avelios Medical and thus expanding the technology partnership between the Munich healthtech startup and SAP that launched in February. The goal is to build an open, interoperable, and AI-native digital healthcare ecosystem for Europe. The core platform is the Avelios hospital information system.

Rnatics is developing RCS-21, a novel inhalable drug against lung inflammation and idiopathic pulmonary fibrosis. The startup was founded in 2021 as a spin-off from TUM by Stefan Engelhardt together with Thomas Frischmuth and Klaus Rabe. After promising research and ongoing clinical studies, the team aims to reach the next milestones and create new therapy options for patients. Clinical lead and pharmacist with a PhD, Christina Beck, explains the details about the founding and mission to us.

Munich-based biotech unicorn Tubulis is being acquired by US company Gilead for a multibillion-euro amount.

The Munich-based biotech startup Rnhale develops inhalable RNA therapeutics as dry powder – faster, simpler, and more efficient than previous approaches. This is intended to treat respiratory diseases such as COPD or asthma in a targeted manner. CEO Benjamin Winkeljann explains in an interview why the path from research to product is challenging and what hurdles almost caused them to fail.

Mpiriq connects medical healthcare and research using artificial intelligence. The platform structures data from practices and hospitals, automates documentation and thus enables faster studies and better therapies – without additional effort in daily work. The team explains how it works and why trust is crucial in an interview.

Munich-based software provider Avelios Medical receives a strategic investment from SAP. Together, the partners are developing a new digital platform for hospitals, responding to the planned replacement of central IT systems in the clinical market.

The Munich biotech startup Rnatics secures €2.7 million in federal funding. The funds will support clinical development of an inhalable RNA therapeutic for inflammatory and fibrotic lung diseases.

Munich-based medtech startup Custom Surgical receives 3.5 million euros from Ventech, Zeiss, and other investors. With the pre-Series A round, the company is advancing the digitalization of workflows in ophthalmology and its international expansion.

Smartbax develops innovative antibiotics against multidrug-resistant bacteria with a completely new mechanism of action: instead of blocking processes, they cause pathogens to self-destruct. Emerging from research at TU München, the startup is working on clinical trials while fighting against the resistance crisis and market hurdles.